Probiotic normalization of Candida albicans in schizophrenia

A randomized, placebo-controlled, longitudinal pilot study

Emily G Severance, Kristin L. Gressitt, Cassie R. Stallings, Emily Katsafanas, Lucy A. Schweinfurth, Christina L G Savage, Maria B. Adamos, Kevin M. Sweeney, Andrea E. Origoni, Sunil Khushalani, Faith B. Dickerson, Robert H Yolken

Research output: Contribution to journalArticle

Abstract

The molecules and pathways of the gut-brain axis represent new targets for developing methods to diagnose and treat psychiatric disorders. Manipulation of the gut microbiome with probiotics may be a therapeutic strategy with the potential to relieve gastrointestinal (GI) comorbidities and improve psychiatric symptoms. . Candida albicans and . Saccharomyces cerevisiae, commensal yeast species, can be imbalanced in the unhealthy human microbiome, and these fungal exposures were previously found elevated in schizophrenia. In a longitudinal, double-blind, placebo-controlled, pilot investigation of 56 outpatients with schizophrenia, we examined the impact of probiotic treatment on yeast antibody levels, and the relationship between treatment and antibody levels on bowel discomfort and psychiatric symptoms. We found that probiotic treatment significantly reduced . C. albicans antibodies over the 14-week study period in males, but not in females. Antibody levels of . S. cerevisiae were not altered in either treatment group. The highest levels of bowel discomfort over time occurred in . C. albicans-seropositive males receiving the placebo. We observed trends towards improvement in positive psychiatric symptoms in males treated with probiotics who were seronegative for . C. albicans. Results from this pilot study hint at an association of . C. albicans seropositivity with worse positive psychiatric symptoms, which was confirmed in a larger cohort of 384 males with schizophrenia. In conclusion, the administration of probiotics may help normalize . C. albicans antibody levels and . C. albicans-associated gut discomfort in many male individuals. Studies with larger sample sizes are warranted to address the role of probiotics in correcting . C. albicans-associated psychiatric symptoms.

Original languageEnglish (US)
JournalBrain, Behavior, and Immunity
DOIs
StateAccepted/In press - Sep 2 2016

Fingerprint

Probiotics
Candida albicans
Longitudinal Studies
Schizophrenia
Placebos
Psychiatry
Antibodies
Saccharomyces cerevisiae
Yeasts
Therapeutics
Microbiota
Mental Disorders
Sample Size
Comorbidity
Outpatients
Brain

Keywords

  • Autism
  • Fungus
  • Gastroenterology
  • Infection
  • Mental health
  • Sex differences

ASJC Scopus subject areas

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

Cite this

Probiotic normalization of Candida albicans in schizophrenia : A randomized, placebo-controlled, longitudinal pilot study. / Severance, Emily G; Gressitt, Kristin L.; Stallings, Cassie R.; Katsafanas, Emily; Schweinfurth, Lucy A.; Savage, Christina L G; Adamos, Maria B.; Sweeney, Kevin M.; Origoni, Andrea E.; Khushalani, Sunil; Dickerson, Faith B.; Yolken, Robert H.

In: Brain, Behavior, and Immunity, 02.09.2016.

Research output: Contribution to journalArticle

Severance, EG, Gressitt, KL, Stallings, CR, Katsafanas, E, Schweinfurth, LA, Savage, CLG, Adamos, MB, Sweeney, KM, Origoni, AE, Khushalani, S, Dickerson, FB & Yolken, RH 2016, 'Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study', Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2016.11.019
Severance, Emily G ; Gressitt, Kristin L. ; Stallings, Cassie R. ; Katsafanas, Emily ; Schweinfurth, Lucy A. ; Savage, Christina L G ; Adamos, Maria B. ; Sweeney, Kevin M. ; Origoni, Andrea E. ; Khushalani, Sunil ; Dickerson, Faith B. ; Yolken, Robert H. / Probiotic normalization of Candida albicans in schizophrenia : A randomized, placebo-controlled, longitudinal pilot study. In: Brain, Behavior, and Immunity. 2016.
@article{e6856af994214c62a8c0b968a03ded63,
title = "Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study",
abstract = "The molecules and pathways of the gut-brain axis represent new targets for developing methods to diagnose and treat psychiatric disorders. Manipulation of the gut microbiome with probiotics may be a therapeutic strategy with the potential to relieve gastrointestinal (GI) comorbidities and improve psychiatric symptoms. . Candida albicans and . Saccharomyces cerevisiae, commensal yeast species, can be imbalanced in the unhealthy human microbiome, and these fungal exposures were previously found elevated in schizophrenia. In a longitudinal, double-blind, placebo-controlled, pilot investigation of 56 outpatients with schizophrenia, we examined the impact of probiotic treatment on yeast antibody levels, and the relationship between treatment and antibody levels on bowel discomfort and psychiatric symptoms. We found that probiotic treatment significantly reduced . C. albicans antibodies over the 14-week study period in males, but not in females. Antibody levels of . S. cerevisiae were not altered in either treatment group. The highest levels of bowel discomfort over time occurred in . C. albicans-seropositive males receiving the placebo. We observed trends towards improvement in positive psychiatric symptoms in males treated with probiotics who were seronegative for . C. albicans. Results from this pilot study hint at an association of . C. albicans seropositivity with worse positive psychiatric symptoms, which was confirmed in a larger cohort of 384 males with schizophrenia. In conclusion, the administration of probiotics may help normalize . C. albicans antibody levels and . C. albicans-associated gut discomfort in many male individuals. Studies with larger sample sizes are warranted to address the role of probiotics in correcting . C. albicans-associated psychiatric symptoms.",
keywords = "Autism, Fungus, Gastroenterology, Infection, Mental health, Sex differences",
author = "Severance, {Emily G} and Gressitt, {Kristin L.} and Stallings, {Cassie R.} and Emily Katsafanas and Schweinfurth, {Lucy A.} and Savage, {Christina L G} and Adamos, {Maria B.} and Sweeney, {Kevin M.} and Origoni, {Andrea E.} and Sunil Khushalani and Dickerson, {Faith B.} and Yolken, {Robert H}",
year = "2016",
month = "9",
day = "2",
doi = "10.1016/j.bbi.2016.11.019",
language = "English (US)",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Probiotic normalization of Candida albicans in schizophrenia

T2 - A randomized, placebo-controlled, longitudinal pilot study

AU - Severance, Emily G

AU - Gressitt, Kristin L.

AU - Stallings, Cassie R.

AU - Katsafanas, Emily

AU - Schweinfurth, Lucy A.

AU - Savage, Christina L G

AU - Adamos, Maria B.

AU - Sweeney, Kevin M.

AU - Origoni, Andrea E.

AU - Khushalani, Sunil

AU - Dickerson, Faith B.

AU - Yolken, Robert H

PY - 2016/9/2

Y1 - 2016/9/2

N2 - The molecules and pathways of the gut-brain axis represent new targets for developing methods to diagnose and treat psychiatric disorders. Manipulation of the gut microbiome with probiotics may be a therapeutic strategy with the potential to relieve gastrointestinal (GI) comorbidities and improve psychiatric symptoms. . Candida albicans and . Saccharomyces cerevisiae, commensal yeast species, can be imbalanced in the unhealthy human microbiome, and these fungal exposures were previously found elevated in schizophrenia. In a longitudinal, double-blind, placebo-controlled, pilot investigation of 56 outpatients with schizophrenia, we examined the impact of probiotic treatment on yeast antibody levels, and the relationship between treatment and antibody levels on bowel discomfort and psychiatric symptoms. We found that probiotic treatment significantly reduced . C. albicans antibodies over the 14-week study period in males, but not in females. Antibody levels of . S. cerevisiae were not altered in either treatment group. The highest levels of bowel discomfort over time occurred in . C. albicans-seropositive males receiving the placebo. We observed trends towards improvement in positive psychiatric symptoms in males treated with probiotics who were seronegative for . C. albicans. Results from this pilot study hint at an association of . C. albicans seropositivity with worse positive psychiatric symptoms, which was confirmed in a larger cohort of 384 males with schizophrenia. In conclusion, the administration of probiotics may help normalize . C. albicans antibody levels and . C. albicans-associated gut discomfort in many male individuals. Studies with larger sample sizes are warranted to address the role of probiotics in correcting . C. albicans-associated psychiatric symptoms.

AB - The molecules and pathways of the gut-brain axis represent new targets for developing methods to diagnose and treat psychiatric disorders. Manipulation of the gut microbiome with probiotics may be a therapeutic strategy with the potential to relieve gastrointestinal (GI) comorbidities and improve psychiatric symptoms. . Candida albicans and . Saccharomyces cerevisiae, commensal yeast species, can be imbalanced in the unhealthy human microbiome, and these fungal exposures were previously found elevated in schizophrenia. In a longitudinal, double-blind, placebo-controlled, pilot investigation of 56 outpatients with schizophrenia, we examined the impact of probiotic treatment on yeast antibody levels, and the relationship between treatment and antibody levels on bowel discomfort and psychiatric symptoms. We found that probiotic treatment significantly reduced . C. albicans antibodies over the 14-week study period in males, but not in females. Antibody levels of . S. cerevisiae were not altered in either treatment group. The highest levels of bowel discomfort over time occurred in . C. albicans-seropositive males receiving the placebo. We observed trends towards improvement in positive psychiatric symptoms in males treated with probiotics who were seronegative for . C. albicans. Results from this pilot study hint at an association of . C. albicans seropositivity with worse positive psychiatric symptoms, which was confirmed in a larger cohort of 384 males with schizophrenia. In conclusion, the administration of probiotics may help normalize . C. albicans antibody levels and . C. albicans-associated gut discomfort in many male individuals. Studies with larger sample sizes are warranted to address the role of probiotics in correcting . C. albicans-associated psychiatric symptoms.

KW - Autism

KW - Fungus

KW - Gastroenterology

KW - Infection

KW - Mental health

KW - Sex differences

UR - http://www.scopus.com/inward/record.url?scp=85007502866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007502866&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2016.11.019

DO - 10.1016/j.bbi.2016.11.019

M3 - Article

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

ER -